Exelixis shares climb on strong sales and earnings, but risk-reward remains unattractive after big run

What happened

Exelixis shares have risen sharply over the past year, up 43.5%, driven by strong sales and earnings, with institutional support. The company's Cabometyx franchise continues to grow, and recent financial results beat expectations. However, the stock now trades at around 17x forward earnings and has become a crowded momentum name. The DeepValue master report maintains a WAIT rating, noting that the risk/reward is skewed to the downside at these levels given single-product concentration and upcoming patent cliffs. The recent news article highlighting the share price gain does not alter the underlying investment thesis, which hinges on Cabometyx durability and zanzalintinib regulatory success.

Implication

The sharp rise in Exelixis shares reflects strong operational execution and institutional buying, but the market may be pricing in too much certainty. At current valuation, the stock offers limited margin of safety, with downside risks from generic competition and policy-driven pricing pressure not adequately discounted. The master report's WAIT rating and $38 attractive entry point suggest that investors should exercise patience rather than buy at these levels. Positive news flow does not change the fundamental risk profile, which remains highly dependent on a single product and an unproven pipeline. A disciplined approach would be to hold existing positions but not add until either a better entry point or clearer de-risking of the zanzalintinib opportunity emerges.

Thesis delta

No material change to thesis. The news article confirms positive momentum and institutional support but does not provide new information that alters the prior WAIT rating. The core risk remains single-product dependence and limited margin of safety at current prices; the stock's run further reduces attractiveness from a risk-reward perspective.